Skip to content

Prevention of Familial Risk of Colorectal Carcinoma

Prevention of Familial Risk of Colorectal Carcinoma - FARKOR

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00015097
Enrollment
90000
Registered
2019-01-15
Start date
2018-10-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C18 C19 C20 D12

Interventions

Group 1: Members of statutory health insurance between 25 and 50 years living in Bavaria are invited to participate in the study. Based on a short questionnaire on their family history of colorectal

Sponsors

Kassenärztliche Vereinigung Bayerns
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 50 Years

Inclusion criteria

Inclusion criteria: 25 -> 50 year-old persons of both genders, with and without family history of CRC, who gave their written consent to participate in the project

Exclusion criteria

Exclusion criteria: Individuals for whom adequate CRC related screening measures already exist are excluded from the study. In particular, patients with an increased risk of CRC due to a known disease (family history of adenomatous polyposis, chronic inflammatory bowel diseases (ulcerative colitis, Chron's disease)) or with a previous diagnosis of CRC will be excluded, as well as patients over 50 years of age for whom CRC screening already exists.

Design outcomes

Primary

MeasureTime frame
The incidence of adenoma and of CRC in study participants who undergo one of the proposed screening options will be measured in the context of this screening option. The incidence of adenoma and of CRC in study participants who do not participate in any screening measures and in those who do not participate in the program will be estimated based on administrative health records during the project period. The statistical analysis will take the difference in detection probabilities of adenoma and of CRC in the different groups in account.

Secondary

MeasureTime frame
- participation rate - number of complications arising in the screening colonoscopies in the program - positive predictive value of iFOBT (immunological fecal occult blood test): frequency of true and false positive findings

Countries

Germany

Contacts

Public ContactPatrizia Ungar

Kassenärztliche Vereinigung Bayerns (KVB) FARKOR Koordinationsstelle

FARKOR@KVB.de0049 89 5 70 93 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 18, 2026